Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 11(65), 2021

DOI: 10.1128/aac.00846-21

Links

Tools

Export citation

Search in Google Scholar

Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms

Journal article published in 2021 by Ayesha Khan ORCID, Samuel G. Erickson, Cedric Pettaway, Cesar A. Arias, William R. Miller ORCID, Micah M. Bhatti ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) producing metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. The combination of aztreonam (ATM) with ceftazidime-avibactam (CZA) is a potential therapeutic option, but there is no approved, feasible testing method for use in clinical laboratories to assess the activity of two antimicrobials in combination.